RO-317549

N/A

Report date: 2022/08/23 20:00:44

Base Information

Drug NameRO-317549
Drug Alias NameRO-318161
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProtein kinase C inhibitors
TargetsProtein kinase C
Therapy Area/IndicationsAtherosclerosisCoronary RestenosisAsthma +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerlandUnited Kingdom
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesF. Hoffmann-La Roche Ltd
Active IndicationsN/A
Inactive IndicationsAtherosclerosisCoronary RestenosisAsthma +[5] 

Other Information

ATC CodeN/A
Related LinksN/A